Inflarx NV logo

IFRX - Inflarx NV News Story

$3.67 -0.0  -0.8%

Last Trade - 19/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £115.7m
Enterprise Value £45.9m
Revenue £n/a
Position in Universe 4718th / 6847

BRIEF-Inflarx NV Says Phase II Trial In Patients With Cutaneous Squamous Cell Carcinoma To Start In First Half 2021

Mon 11th January, 2021 2:07pm
Jan 11 (Reuters) - Inflarx NV  IF0G.DE :
    * INFLARX NV - PROVIDES UPDATE ON VILOBELIMAB (IFX-1)
DEVELOPMENT
    * INFLARX NV - PHASE II TRIAL IN PATIENTS WITH CUTANEOUS
SQUAMOUS
CELL CARCINOMA EXPECTED TO START IN FIRST HALF OF 2021
    * INFLARX NV - PLANS TO SUBMIT A SPECIAL PROTOCOL ASSESSMENT
TO
FDA FOR PHASE III TRIAL IN HIDRADENITIS SUPPURATIVA IN Q1 OF
2021
    * INFLARX NV -  TOPLINE DATA FROM COVID-19 TRIAL ARE
EXPECTED TO
BE AVAILABLE IN 2021

Source text for Eikon:  ID:nGNX8HCvnz 
Further company coverage:  IF0G.DE 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.